Skip to main content

Aligos Therapeutics Inc(ALGS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Globe Newswire - Thu Mar 10, 2022

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b
ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolled
siRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studies
THR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemia
Multiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvir
Merck expanded the NASH research collaboration utilizing Aligos’ proprietary oligonucleotide technology

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe